It has been demonstrated that oral administration of JDYZF reversed Aβ25–35-induced cognitive impairment, reduced Aβ deposition, and improved neuronal function by inhibiting the expression of NLRP3/caspase-1/GSDMD and LPS/caspase-11/GSDMD axis (Wang et al., 2022). Here, GSDMD is linked to Cognitive impairment.